Company profile: Akarna Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical research and development of novel small molecule therapeutics targeting inflammatory and fibrotic diseases, including a non-bile acid FXR agonist for nonalcoholic steatohepatitis (NASH), aiming to deliver best-in-class treatments for chronic liver diseases.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Akarna Therapeutics
Metacrine
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on building an innovative pipeline of best-in-class drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Metacrine company profile →
Ocera Therapeutics
HQ: United States
Website
- Description: Provider of novel therapeutics in development for patients with acute and chronic liver disease, as a clinical-stage biopharmaceutical company focused on development and commercialization in an area of high unmet medical need; HE clinical development includes a recently completed Phase 2b trial, STOP-HE, which evaluated safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ocera Therapeutics company profile →
Calliditas Therapeutics
HQ: Sweden
Website
- Description: Provider of specialty pharmaceuticals for unmet medical needs in niche indications, including TARPEYO (delayed-release budesonide for renal diseases), Kinpeygo (renal and hepatic diseases), NEFECON (candidate for primary IgA nephropathy), and Setanaxib (NOX1/4 inhibitor in trials for PBC and head & neck cancer), plus pipeline development for orphan renal/hepatic diseases and strategic partnerships for development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calliditas Therapeutics company profile →
Inozyme Pharma
HQ: United States
Website
- Description: Provider of therapies for rare diseases of calcification affecting soft tissues and bone, including a clinical-stage enzyme therapy (INZ-701) for pathologic mineralization and intimal proliferation in ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. Conducts clinical trials, offers a genetic testing process for ENPP1 Deficiency, and provides patient and family support and community resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inozyme Pharma company profile →
Aurinia Pharmaceuticals
HQ: Canada
Website
- Description: Provider of therapies for serious autoimmune diseases, including LUPKYNIS (voclosporin), an FDA-approved oral treatment for adult patients with active lupus nephritis; conducts R&D to address unmet needs; offers patient education and advocacy programs; and partners with global academia, research, and industry to develop and commercialize treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aurinia Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Akarna Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Akarna Therapeutics
2.2 - Growth funds investing in similar companies to Akarna Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Akarna Therapeutics
4.2 - Public trading comparable groups for Akarna Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →